[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sexually-transmitted-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sexually-transmitted-infection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,79,117,139,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100615271","improving-maternal-and-child-health-through-point-of-care-sti-testing-100615271",false,"NCT07290439","Improving Maternal and Child Health Through Point-of-care STI Testing","Improving Maternal and Child Health Through Point-of-care STI Testing (MATCH-POINT)","MATCH-POINT","Inclusion Criteria:\n\n* Pregnant and clinically indicated for STI testing (syphilis and\u002For Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) at a prenatal care (PNC ) or labor and delivery (L\\&D) triage visit at Grady Memorial Hospital (GMH). Indications for STI testing in pregnancy at GMH:\n\n  * Syphilis, CT, NG, and TV indicated at first PNC visit\n  * Syphilis serologic testing additionally indicated in 3rd trimester and at delivery\n  * CT\u002FNG\u002FTV additionally indicated in the 3rd trimester for those \\\u003C25 or with increased risk \\[1\\]\n  * Additional testing recommended based on clinical signs or symptoms (e.g., genital lesion or vaginal discharge, new exposure history)\n* English or Spanish-speaking\n* If \\\u003C16 years of age, has a parent or legal guardian present\n* Have STI risk factor:\n\n  * \\\u003C25 years of age\n  * Reports current substance use\n  * Reported or documented history of a positive STI\n  * More than one current sex partner\n  * A current sex partner who has concurrent partners\n  * A new sex partner (\\\u003C6 months )\n  * A current sex partner who has an STI\n  * Exchange of sex for money or drugs\n  * Incarceration\n  * No previous prenatal care during the current pregnancy\n* Able to follow study procedures and provide written informed consent or assent, as appropriate\n\nExclusion Criteria:\n\n* Indicated for syphilis test: negative RPR test during this pregnancy\n* Indicated for syphilis test: ever had a previous syphilis diagnosis (lifetime history)\n* Indicated for CT\u002FNG\u002FTV test: negative for all three of CT, NG, and TV within the previous 1 month\n* Indicated for CT\u002FNG\u002FTV test: positive for any of CT, NG, and\u002For TV and completed treatment \\\u003C3 weeks prior\n\nStakeholders:\n\n* GMH PNC or L\\&D providers, GMH leadership, Georgia Dept of Health leadership\n* \\>=18 years of age\n* Able to follow study procedures and provide verbal informed consent",true,"FEMALE",{"count":20,"type":21},756,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if point-of-care tests (POCTs) for sexually transmitted infections (STIs) improve the timely treatment of syphilis, chlamydia, gonorrhea, and trichomonas in pregnant women. It will also learn about the feasibility, acceptability, and cost-effectiveness of implementing POCTs in a large safety-net hospital setting.\n\nThe main questions it aims to answer are:\n\n* Do POCTs reduce delays in STI treatment compared with standard laboratory-based testing?\n* What barriers, facilitators, and processes affect POCT implementation in prenatal and obstetric care?\n* What are the costs and cost-effectiveness of POCTs compared with standard testing?\n\nParticipants will:\n\n* Complete a baseline survey and receive either POCTs (fingerstick blood draw or vaginal swab) or standard laboratory STI testing.\n* If diagnosed with an STI, complete a follow-up survey approximately one month later.\n* Stakeholders (providers, hospital leadership, and public health officials) will complete interviews to inform implementation strategies.",[27,28,29,30,31],"Treponema Pallidum Infection","Chlamydia Trachomatis Infection","Neisseria Gonorrheae Infection","Trichomonas Vaginalis Vaginitis","Sexually Transmitted Infection",[33,34],"Prenatal care","Point of care test","RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-19","ACTUAL",{"date":41,"type":39},"2026-08-11",{"date":43,"type":21},"2030-06",{"name":45,"class":46},"Emory University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100650928","characterization-of-doxycycline-pharmacokinetics-and-adherence-100650928","NCT07755618","Characterization of Doxycycline Pharmacokinetics and Adherence","Characterization of Doxycycline Pharmacokinetics and Adherence Post-Single and Repeat Dosing Schemas","Inclusion Criteria:\n\n1. Aged 18 to 65 years of age at the time of screening\n2. Able and willing to follow study participation requirements and provide informed consent to take part in the study\n3. Has a non-reactive\u002Fnegative HIV test results at screening per applicable algorithm\n4. Has and is able to maintain a caput (head) of hair, that has not been chemically treated (defined as hair that has been bleached, permed, relaxed or dyed\u002Fcolored) and is greater than one centimeter in length for the duration of the study\n5. For females of reproductive potential: Has a negative urine pregnancy test at screening\n6. For females of reproductive potential: Using at least two effective methods of contraception for at least 30 days (inclusive) prior to enrollment and intending to use two effective methods of contraception for the duration of study participation. It is strongly recommended that at least one barrier method (e.g. condoms) in addition to a hormonal contraception method be used. Examples of acceptable and effective methods include:\n\n   1. Hormonal methods (oral pills, vaginal ring, depo, transdermal or implant)\n   2. Intrauterine device (IUD) inserted at least 30 days prior to enrollment\n   3. Surgical sterilization (of participant or partner(s)) including bilateral tubal ligation or vasectomized male partners\n   4. Barrier methods (condom with\u002Fwithout spermicide, sponge, cervical cap, diaphragm)\n   5. Self-identifies as having same sex partners\n   6. Self-reported sexually abstinent as defined by abstaining from penile-vaginal intercourse for 90 days prior to enrollment and intending to remain sexually abstinent for the duration of study participation\n7. Has access to a smartphone and\u002For laptop and is able and willing to participate in video-based communications with study staff for directly observed dosing requirements\n8. In good general health, in the opinion of the investigator of record (IoR) or designee and has no medical condition that would adversely impact the conduct of the study (inclusive of self-reported conditions and\u002For those found upon medical history and examination or in available medical records). This includes, but is not limited to, having an intact, healthy gastrointestinal tract (without damage or functional disruption) and the ability to swallow pills\n\nExclusion Criteria:\n\n1. Per participant report, planned or active use of any anticonvulsants at screening and an unwillingness to restrict use of certain medications (iron, antacids, etc.) for the duration of the study\n2. For females of reproductive potential: Pregnant or currently breastfeeding, or intends to become pregnant and\u002For breastfeed during the study\n3. Has any of the following laboratory abnormalities:\n\n   1. An estimated calculated creatinine clearance (CrCl) less than 60 mL\u002Fmin by the Cockcroft-Gault formula at screening\n   2. Positive for hepatitis B surface antigen (HBsAg) at screening\n   3. Has a Grade 2 or higher clinically significant laboratory abnormality as defined by The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 - July 2017 (exception: a CrCl ≥ 60 mL\u002Fmin at enrollment is permissible for enrollment)\n4. Per participant reported symptoms or clinical and\u002For laboratory diagnosis of an active pharyngeal, anorectal, or reproductive tract infection (RTI) requiring treatment at screening and enrollment per current US Centers for Disease Control and Prevention (CDC) guidelines (https:\u002F\u002Fwww.cdc.gov\u002Fstd\u002Ftreatment-guidelines\u002Fdefault.htm). Infections requiring treatment include Neisseria gonorrhoeae (GC), Chlamydia trachomatis (CT), syphilis, active herpes simplex virus (HSV) lesions, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), bacterial vaginosis (BV), symptomatic vaginal candidiasis, and trichomoniasis\n5. Participation in research studies involving drugs, products, or vaccines within 30 days of the enrollment and for the duration of the study\n6. Has donated blood within 8 weeks of enrollment of approximately 1 pint (550 mL)\n7. Has a known allergy (adverse reaction) to any of the components of the study product, including known hypersensitivity to tetracycline-class antibiotics\n8. Prior use of doxycycline or any other tetracycline-class antibiotic within 30 days prior to enrollment\n9. Has an active infection that may be responsive to treatment with doxycycline or another tetracycline antibiotic\n10. Has evidence or history of any other condition (e.g., gastrectomy, seizure disorder), that, in the opinion of the IoR or designee, would make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives","ALL","18 Years","65 Years",{"count":59,"type":21},16,[61],"PHASE1","The purpose of this study is to evaluate the effect of body changes on doxycycline concentrations for different dosing schedules. This study will involve a single dose phase and a multiple dose phase. Healthy individuals who do not have a sexually transmitted infection (STI), including acute (e.g., gonorrhea or chlamydia) or chronic (e.g., HIV or HSV-2) infections will be enrolled in this study. Study participants will be randomized to a dosing schedule in each phase and come to the research clinic throughout their time on study for sample collection. Study participants that choose to enroll in this study will be enrolled for about 37 days.",[31],[65,66,67],"Doxycycline","Pharmacokinetics","PK Sampling","NOT_YET_RECRUITING","2026-08-05",{"date":71,"type":39},"2026-08-10",{"date":73,"type":21},"2026-08-01",{"date":75,"type":21},"2027-07-01",{"name":77,"class":78},"HIV Prevention Trials Network","NETWORK",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":17,"sex":86,"minAge":56,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},"100641835","phase-3-duo-a-phase-iiib-individual-level-randomized-controlled-trial-of-an-integrated-strategy-100641835","NCT07658976","Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy","Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV PrEP and STI PEP for Young Men","Inclusion Criteria:\n\n1. Men ages 18 - 29 years\n2. Men who are in communities most affected by the HIV epidemic\n3. Willing and able to provide informed consent\n4. Reports having anal sex with men in the last 6 months\n5. Have certain risk factors for HIV acquisition, defined as any of the following in the past 6 months:\n\n   1. Any condomless anal sex with a man; not including within a monogamous relationship with an HIV-negative partner or an HIV-positive partner who is virally suppressed\n   2. Reporting 2 or more male partners, regardless of condom use\n   3. Reporting gonorrhea, chlamydia, or syphilis diagnosis\n   4. Any stimulant use (e.g., cocaine, amphetamines)\n6. Not on PrEP within the past 3 months due to participant choice\n7. Interested in learning more about PrEP or starting PrEP\n8. No evidence of HIV infection at Screening and Enrollment, based on the HIV testing algorithm\n9. Owns an iOS or Android mobile phone and able to successfully download mobile apps and send and receive text messages\n10. Must not share the mobile phone used for their participation in the study\n11. Able to read and write\n\nExclusion Criteria:\n\n1. Participated in HPTN 113-01\n2. Currently participating in another interventional trial of PrEP agents, or prior enrollment in studies of long-acting PrEP, including HPTN 083\n3. Plans to move away from the study area within the next year\n4. Currently on doxycycline for STI PEP\n5. Has ever used CAB-LA or other long-acting PrEP agent\n6. Tetracycline allergy\n7. Prior diagnosis of HIV infection\n8. Reactive HIV rapid test at Screening or reactive HIV Ag\u002FAb rapid test at Enrollment, regardless of subsequent HIV test results\n9. Any other condition that, in the opinion of the Investigator of Record (IoR)\u002Fdesignee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable\u002Funwilling to comply with the study requirements","MALE","29 Years",{"count":89,"type":21},400,[91],"PHASE3","Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men",[94,31],"HIV Infection",[96,97,98,99,100,101,102,103,104,105,106,107],"Human Immunodeficiency Virus (HIV)","Sexually Transmitted Infection (STI)","Pre-Exposure Prophylaxis (PrEP)","Post-Exposure Prophylaxis (PEP)","Integrated Strategy","Young Men","Doxycycline for STI Post-Exposure Prophylaxis (Doxy-PEP)","Chlamydia Trachomatis (CT)","Neisseria Gonorrhea (NG)","Hepatitis B (HBV)","Mobile Health Tools (mHealth)","MyPrEP + PrEPmate + PrEPsmart Tools (3P)","2026-06-15",{"date":110,"type":39},"2026-06-22",{"date":112,"type":21},"2026-09-01",{"date":114,"type":21},"2029-09-01",{"name":77,"class":78},5,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":47},"100458080","epidemiology-of-sexually-transmitted-infections-and-its-impact-on-female-infertility-100458080","NCT05244967","Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility","ESTIMATE","Inclusion Criteria:\n\n* 18-22 years\n* informed consent\n\nExclusion Criteria:\n\n* pregnancy\n* sterilization\n* not capable of giving informed consent","22 Years",{"count":126,"type":21},533,"OBSERVATIONAL","A longitudinal study to investigate the prevalence of sexually transmitted infections among young women and determine the role of the female genital tract microbiome in fertility",[31],"2026-04-29",{"date":132,"type":39},"2026-04-30",{"date":134,"type":39},"2020-11-11",{"date":136,"type":21},"2029-06-30",{"name":138,"class":46},"University of Luebeck",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":159,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100574980","integrated-care-versus-usual-care-for-opioid-use-disorder-and-infectious-diseases-in-veterans-100574980","NCT06766331","Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder","Inclusion Criteria:\n\n* US Veteran\n* Able to provide written informed consent in English\n* Living in the community (Nassau, Suffolk, Kings, Queens, Bronx, Westchester, Rockland counties, NY)\n* Documented diagnosis of moderate to severe opioid use disorder\n* Seeking care at the Northport VA substance use disorder clinic for opioid use disorder treatment\n* Willing to have HIV, HBV, HCV, or bacterial STI testing to determine negative or positive status\n* Persons who test negative for HIV need to meet CDC PrEP eligibility criteria in the 6 months prior to enrollment\n\nExclusion Criteria:\n\n* Severe medical or psychiatric disability making participation unsafe\n* Unable to provide written consent\n* PrEP exclusion: HIV positive test; HBV positive test",{"count":147,"type":21},60,[24],"Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.",[151,152,153,154,155,156,31,157,158],"Opioid Use Disorder","HIV","Hepatitis C Virus","Gonorrhea","Chlamydia","Syphilis","Integrated Care","Medications for Opioid Use Disorder",[160,152,161,162],"Hepatitis C","sexually transmitted diseases","Opioid-Related Disorders","2026-04-21",{"date":165,"type":39},"2026-04-24",{"date":167,"type":21},"2028-04-03",{"date":169,"type":21},"2029-06-29",{"name":171,"class":172},"VA Office of Research and Development","FED",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":47},"100623580","prepwise-pilot-among-black-women-in-eastern-virginia-100623580","NCT07398482","PrEPwise Pilot Among Black Women in Eastern Virginia","Feasibility and Preliminary Effectiveness of PrEPwise Intervention on PrEP Initiation Among Black Women in Eastern Virginia","PrEPwise","Inclusion Criteria:\n\n* Black women seeking HIV testing services at the community HIV testing clinic\n* Eligible for PrEP according to CDC guidelines\n* Willing to be followed for 3 months\n* Able to provide contact information\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Participated in the development of the intervention (provided input in the adaptation of PrEP decision aid)\n* Unable to provide informed consent\n* Unable to provide contact information\n* Currently using PrEP",{"count":182,"type":21},108,[24],"HIV is a virus that affects many people, but Black women in the U.S. are a population at a much higher risk of getting it compared to white women-about 18 times higher. Pre-exposure prophylaxis (PrEP), a medicine if taken as recommended by a clinician can prevent HIV almost completely (99% effective). The problem is that many Black women, especially those living in the Southern U.S., don't know about this medicine called PrEP or find it hard to access it. To address this, healthcare providers sometimes use \"decision aids\" which are tools, like brochures or videos, designed to help people understand their medical options and make informed choices based on what's important to them. While these tools have worked well for other health issues, they haven't been widely used for preventing HIV. The challenges are doctors do not have enough time to explain PrEP fully to patients during clinic visits and also some Black women do not trust the healthcare system because of a long history of unfair treatment toward Black communities.\n\nCommunity health workers (CHWs) are trained health workers from the same communities as their patients and can facilitate their ability to provide culturally appropriate health education and information consistent with patients' values and needs. Because of this, patients are often more comfortable talking to them. This project aims to test the acceptability and effectiveness of a decision tool to be integrated into HIV testing services to help Black women decide if PrEP is right for them. The investigators are calling this intervention PrEPwise. A tool originally designed for women dealing with opioid addiction will be adapted to fit the needs of Black women living in the South. The long-term goal of this project is to make it easier for Black women to learn about PrEP and decide whether to use it, ultimately helping lower the number of new HIV cases in Black women.",[186,31],"HIV Infections",[98,188],"Community Health Worker (CHW)","2026-02-09",{"date":191,"type":39},"2026-02-11",{"date":193,"type":21},"2027-04",{"date":195,"type":21},"2028-07",{"name":197,"class":46},"Boston University"]